News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling
Preclinical data provide new mechanistic insights linking tenapanor's analgesic action to a well-established pain pathway for the treatment of patients with IBS-C FREMONT, Calif. , Oct. 16, 2017 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today reported that data from preclinical studies have
View HTML
Toggle Summary Ardelyx's Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018
Six of 12-week combined responder rate shows clear benefit in treated patients with consistent response throughout 26 weeks Best-in-class, nine of 12-week combined responder rate demonstrates ability to normalize patients' bowel function Conference call to be held today at 4:30 p.m.
View HTML
Toggle Summary Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results
Restructuring Aligns Resources on Execution of Late-Stage Program Milestones<br>T3MPO-2 Phase 3 Trial Results of Tenapanor for IBS-C on Track for Early Fourth Quarter; RDX7675 Onset-of-Action Data Planned for Fourth Quarter<br>Conference Call to be Held at 8:00 a.m. ET Today
View HTML
Toggle Summary Ardelyx Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference
FREMONT, Calif. , Aug. 2, 2017 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) diseases, today announced that management will host a conference call in conjunction with its second
View HTML
Toggle Summary Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
Study achieves primary endpoint; tenapanor well-tolerated in treated patients<br>Company to hold conference call at 8:30 a.m. ET today
View HTML
Toggle Summary Ardelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress
Company on track to report data from T3MPO-1 Phase 3 trial of tenapanor in IBS-C in Q2 2017
View HTML
Toggle Summary Ardelyx To Present at Upcoming Spring Medical Meetings
FREMONT, Calif. , April 18, 2017 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) diseases, today announced that it will present clinical and preclinical data during two poster
View HTML
Toggle Summary Ardelyx Announces Presentation at Cowen and Company 37th Annual Healthcare Conference
FREMONT, Calif. , Feb. 27, 2017 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) diseases, today announced that Mike Raab , chief executive officer of Ardelyx , will present at the
View HTML
Toggle Summary Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results
Announced Positive Data From Phase 3 Trial of Tenapanor in Hyperphosphatemia; Company Plans to Initiate Second Phase 3 Trial Mid-Year 2017<br>Phase 3 T3MPO-1 and T3MPO-2 Trials in IBS-C on Track to Readout By Mid-and End-of-Year 2017
View HTML
Toggle Summary Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
Tenapanor Represents First Small Molecule, Non-Binder Treatment to Demonstrate Statistically Significant Effect in Hyperphosphatemia<br>Tenapanor Exhibits Favorable Tolerability Profile; Company Plans to Initiate Second Phase 3 Trial<br>Company to Host Conference Call Today at 8:30 a.m. ET
View HTML